Last reviewed · How we verify
NCT06127108
Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Panel
NA trial testing Panbio™ in COVID-19 in 447 participants. Completed in 2 February 2024.
2 February 2024
Quick facts
| Lead sponsor | Abbott Rapid Dx |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 447 |
| Start date | 14 November 2023 |
| Primary completion | 2 February 2024 |
| Estimated completion | 2 February 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Panbio™
Conditions studied
- COVID-19 — all drugs for COVID-19 →
- Influenza A — all drugs for Influenza A →
- Influenza B — all drugs for Influenza B →
Sponsor
Abbott Rapid Dx
Who can join
2 and older, any sex, with COVID-19 or Influenza A. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study is designed as a prospective, multicentric, clinical study to investigate the positive percent agreement (PPA) and negative percent agreement (NPA) of the Panbio™ COVID-19/Flu A\&B Panel using anterior nasal swab specimens tested directly, relative to the comparator methods, Roche cobas® SARS-CoV-2 (K231306) and Quidel Lyra® Influenza A+B Assay(K230236) (RT-PCR) in symptomatic patients suspected of respiratory viral infection by a healthcare provider.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06127108
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Panbio™
Trials testing the same drug.
- NCT05715515 — Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Rapid Panel Professional Use Device and the Panbio™ COVID-19/Flu A&B · NA · completed
- NCT05630365 — Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Rapid Panel Professional Use Product Using Mid-Turbinate Nasal Swabs · NA · completed
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other Abbott Rapid Dx trials
Trials by the same sponsor.
- NCT07203183 — Dengue - Sample Collection Study Pakistan · not yet recruiting
- NCT06928129 — Clinical Feasibility of the BinaxNOW™ COVID-19/Flu A&B Combo in the Southern Hemisphere · NA · not yet recruiting
- NCT06492018 — Lay User Evaluation of the Panbio™ HCV Self Test in an EU Population · not yet recruiting
- NCT06395675 — Clinical Evaluation of the ID NOW™ CT/NG Test · NA · not yet recruiting
- NCT06124638 — Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Panel to Support Home Use · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06127108 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Abbott Rapid Dx
- Last refreshed: 25 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06127108.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing